Xequel Bio, Inc.

Activities Focused on Xequel’s Ophthalmic Solution Containing aCT1 Peptide, Being Developed for the Treatment of Persistent Corneal Epithelial Defect and Recurrent Corneal ErosionsSAN DIEGO and GAINESVILLE, Ga., May 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Xequel Bio, Inc. (“Xequel”) to provide CDMO services to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform. The agreement spans a range of Societal CDMO’s offerings including process development and clinical trial services, culminating in cGMP manufacturing of the compound and placebo for upcoming Phase 2 clinical trials of iNexin™ (aCT1 ophthalmic solution). iNexin is a sterile, preservative-free ophthalmic solution containing aCT1 peptide that is currently being evaluated by Xequel for the potential treatment of persistent corneal epithelial defects (PCED). “We are pleased to have been selected by Xequel to continue our support of this important investigational drug candidate in the ophthalmology space. It is gratifying to be able to grow this relationship in lockstep with the advancement of iNexin into the next phase of its clinical development, demonstrating our ability to meet the evolving needs of our customers as they mature their development pipelines,” said David Enloe, chief executive officer of Societal CDMO. “This new agreement is the latest highlight in what has been an active period for our business development, project management, and operations teams. In just the past six weeks, we have announced new customer agreements with Longboard Pharmaceuticals and Xequel, project expansion agreements with several existing customers, and an approval from FDA for manufacturing of a commercial tablet at our Georgia facility. We continue to deliver against our growth strategy and look forward to maintaining the momentum as we move through 2023.” About Societal CDMOSocietal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California. Societal CDMO: Bringing Science to Society. For more information about Societal CDMO’s customer solutions, visit societalcdmo.com. About Xequel Bio, Inc.Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. Xequel’s lead clinical programs include Granexin® gel in dermatology and iNexin™ ophthalmic solution in ophthalmology. For more information, please visit www.xequel.com. Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, among other things, relate to the Company’s expectations regarding the completion of the proposed public offering, the Company’s use of proceeds from the proposed offering, and other statements. The words “anticipate”, “believe”, “could”, “estimate”, “upcoming”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will” and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause the company’s actual outcomes to differ materially from those expressed in or underlying these forward-looking statements include risks and uncertainties associated with demand for the company’s services, which depends in part on customers’ research and development and the clinical plans and market success of their products; customers’ changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with the company’s manufacturing services; the average profitability, or mix, of the products the company manufactures; the company’s ability to enhance existing or introduce new services in a timely manner; fluctuations in the costs, availability, and suitability of the components of the products the company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or the company’s customers facing increasing or new competition. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results presented herein along with those risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

Dublin, July 08, 2021 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market. Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world. Examples of recently approved peptide drugs include (in the reverse chronological order of approval) LupkynisT (2021), Mycappsa (2020), Scenesse (2019), Rybelsus (2019) and Vyleesi (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually. Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry. Amongst other elements, the report features: One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. Key Questions Answered Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET OVERVIEW 5. COMPETITIVE LANDSCAPE5.1. Chapter Overview5.2. Peptide Therapeutics: List of Developers5.2.1. Analysis by Year of Establishment5.2.2. Analysis by Company Size5.2.3. Analysis by Phase of Development and Geography (Logo Landscape)5.2.4. Key Players: Analysis by Number of Product Candidates5.3. Analysis by Company Size, Phase of Development and Geography (Heat Map 6. COMPANY PROFILES6.1. Chapter Overview6.2. Apellis Pharmaceuticals6.2.1 Company Overview6.2.2. Financial Information6.2.3 Pipeline Details6.2.4. Recent Developments and Future Outlook6.3. BioLineRx6.4. Eli Lilly6.5. FirstString Research6.6. Novo Nordisk6.7. Palatin Technologies6.8. RegeneRx Biopharmaceuticals6.9. Stealth BioTherapeutics6.10. Takeda6.11. Zealand Pharma 7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA7.1. Chapter Overview7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused Initiatives7.2.1. Analysis by Number of Amino Acids7.2.2. Analysis by Route of Administration7.2.3. Analysis by Therapeutic Area7.3. Benchmark Analysis of Key Parameters7.3.1. Spider Web Analysis: Pipeline Strength7.3.2. Spider Web Analysis: Partnerships7.3.3. Spider Web Analysis: Investments7.3.4. Spider Web Analysis: Clinical Trials7.4. Benchmark Analysis of Big Pharmaceutical Players7.4.1. Spider Web Analysis: Novo Nordisk7.4.2. Spider Web Analysis: Amgen7.4.3. Spider Web Analysis: Takeda7.4.4. Spider Web Analysis: Eli Lilly7.4.5. Spider Web Analysis: Johnson and Johnson 8. PARTNERSHIPS AND COLLABORATIONS8.1. Chapter Overview8.2. Partnership Models8.3. Peptide Therapeutics: List of Partnerships and Collaborations8.3.1. Analysis by Year of Partnership8.3.2. Analysis by Type of Partnership8.3.3. Analysis by Year and Type of Partnership8.3.4. Analysis by Type of Peptide8.3.5. Analysis by Route of Administration8.3.6. Analysis by Type of Partnership and Route of Administration8.3.7. Analysis by Type of Partnership, Type of Peptide and Route of Administration8.3.8. Analysis by Phase of Development8.3.9. Analysis by Type of Partnership and Phase of Development8.3.10. Analysis by Therapeutic Area8.3.11. Analysis by Year, Type of Partnership and Therapeutic Area (Grid8.4. Most Active Players: Analysis by Number of Partnerships8.5. Regional Analysis8.5.1. Intracontinental and Intercontinental Agreements8.5.2. Local and International Agreements 9. FUNDING AND INVESTMENT ANALYSIS9.1. Chapter Overview9.2. Types of Funding9.3. Peptide Therapeutics: Funding and Investment Analysis9.3.1. Analysis by Number of Funding Instances9.3.2. Analysis by Amount Invested9.3.3. Analysis by Type of Funding9.3.4. Analysis by Year and Type of Funding9.3.5. Analysis of Amount Invested by Geography9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount9.3.7. Key Investors: Analysis by Number of Funding Instances9.3.8. Analysis by Phase of Development9.3.9. Analysis by Therapeutic Area 10. CLINICAL TRIAL ANALYSIS10.1. Chapter Overview10.2. Scope and Methodology10.3. Peptide Therapeutics: Clinical Trial Analysis10.3.1. Analysis by Trial Registration Year10.3.2. Analysis by Trial Status10.3.3. Analysis by Trial Phase10.3.4. Analysis by Trial Recruitment Status10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population10.3.6. Analysis by Study Design10.3.7. Analysis by Type of Sponsor / Collaborator10.3.8. Most Active Players: Analysis by Number of Registered Trials10.3.9. Emerging Focus Area10.3.10. Analysis by Therapeutic Area10.3.11. Geographical Analysis by Number of Registered Trials10.3.12. Geographical Analysis by Enrolled Patient Population 11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS11.1. Chapter Overview11.2. Methodology11.2.1. Assumptions and Key Parameters11.3. Affiliated Insights11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases11.3.2. Clinical and Commercial Attractiveness Analysis: Cardiovascular Diseases11.3.3. Clinical and Commercial Attractiveness Analysis: Central Nervous System11.3.4. Clinical and Commercial Attractiveness Analysis: Digestive and Gastrointestinal 11.3.5. Clinical and Commercial Attractiveness Analysis: Endocrine Diseases11.3.6. Clinical and Commercial Attractiveness Analysis: Genetic Diseases11.3.7. Clinical and Commercial Attractiveness Analysis: Hematological Diseases11.3.8. Clinical and Commercial Attractiveness Analysis: Infectious Diseases11.3.9. Clinical and Commercial Attractiveness Analysis: Inflammatory Diseases11.3.10. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases11.3.11. Clinical and Commercial Attractiveness Analysis: Oncological Diseases11.3.12. Clinical and Commercial Attractiveness Analysis: Ophthalmic Diseases11.3.13. Clinical and Commercial Attractiveness Analysis: Other Diseases 12. CASE STUDY: CONTRACT SERVICES LANDSCAPE12.1.1. Chapter Overview12.2. Role of Service Providers12.2.1. List of Peptide CROs12.2.2. List of Platform Providers12.2.3. List of Peptide CMOs12.2.3.1. List of Custom Peptide Manufacturers12.3. Advantages of Outsourcing12.4. Risks and Challenges Associated with Outsourcing 13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS13.1. Chapter Overview13.2. Overview of Novel Peptide Therapeutics13.3. Advantages and Applications of Novel Peptide Therapeutics13.4. Key Challenges Associated with Novel Peptide Therapeutics 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUDING REMARKS 16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS (2000-2012) 17. APPENDIX II: TABULATED DATA 18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS For more information about this report visit

Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow. DelveInsight’s ‘Corneal Ulcer Pipeline Insights’ report provides the current treatment landscape and rich analysis of pipeline therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the key pointers from the Corneal Ulcer Pipeline report: Discover more about the pharma company and therapy expected to grab maximum share by requesting sample report @ Corneal Ulcer Emerging Therapies and Forecast Corneal Ulcer: Overview Corneal Ulcer, also known as Keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma. Whilst the treatment of refractory corneal ulcers is challenging, it is essential that they are resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea. Discover more about disease outlook, available therapies, and emerging drugs, visit Corneal Ulcer Pipeline Analysis Corneal Ulcer Drug Pipeline Assessment Request for Sample to know more @ Corneal Ulcer Pipeline Analysis, Key Companies, and Futuristic Trends Corneal Ulcer Therapeutics Assessment The Corneal Ulcer Pipeline report lays down a comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action (MoA). By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions Scope of the Corneal Ulcer Pipeline Report Coverage: GlobalKey Players: Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas medicine, and others. Key Corneal Ulcer Pipeline Therapies: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, and others. Reach out @ Corneal Ulcer Pipeline: Novel therapies and Emerging technologies Table of Contents Learn more about the report offerings @ Corneal Ulcer Emerging Therapies, Treatments and Ongoing Clinical Trials Related ReportsCorneal Ulcer MarketDelveInsight's "Corneal Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.Peptic Ulcer Hemorrhage MarketDelveInsight's "Peptic Ulcer Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.Varicose Ulcer MarketDelveInsight's " Varicose Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report. Venous Leg Ulcer MarketDelveInsight's "Venous Leg Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts Global Burden of Cytomegalovirus SeroprevalenceAnalysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News